Melissa Davis

Tenet Transfer Extends L.A. Saga

 

By now, the feds are examining physician relationships at a number of Tenet facilities. The company disclosed just Wednesday, for example, that prosecutors are now seeking information about its San Ramon Regional Medical Center in San Francisco. Still, Tenet continues to maintain that its arrangements with physicians have always been appropriate despite the mounting government scrutiny.

Meanwhile, other members of Centinela Freeman HealthSystem are possible targets of the government as well. The Los Angeles Business Journal reported earlier this year that Apex Cardiology Consultants -- a high-profile practice at Centinela -- has fielded a subpoena and appears to be the focus of an investigation by federal prosecutors. At least two members of that busy cardiology practice are among the group now buying the three L.A. hospitals, based on past emails sent out by Finnigan.

Still, Finnigan himself claimed he didn't know whether Apex is participating in the deal or not. But Edwards at least took a guess.

"I honestly don't know," he said. "But I suspect that they are."

For a variety of reasons, We CAHRE now has fresh worries about the hospital it once saved.

"We will continue to monitor the situation along with other healthcare advocates," Inouye pledged, "as we continue to vie for the Daniel Freeman Marina Hospital."

Skolnick, for one, has already hinted at a possible fight ahead.

"This saga," she declared on Wednesday, "may not be over yet."

>To order reprints of this article, click here: Reprints

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,419.86 1,313.32 2,837.36 16.25
Oil *
103.00
DOWN
160.83
DOWN
19.10
DOWN
33.63
DOWN
1.06
10 Yr
1.62%
SPDR Gold
151.91
-1.28%
-1.43%
-1.17%
-6.12%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet